Literature DB >> 9079798

B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells.

M J Deeths1, M F Mescher.   

Abstract

To characterize better the co-stimulatory activity of native B7-1 in the absence of other receptor/ligand interactions that might contribute to the response, B7-1 was purified by monoclonal antibody (mAb) affinity chromatography. Immobilization of purified B7-1 with anti-T cell receptor (TCR) mAb on cell-sized latex microspheres provided an effective stimulus for activation of both CD4+ and CD8+ T cells as measured by proliferation, development of effector function, and changes in motility and adhesion. The CD4+ T cell response was prolonged and resulted in efficient interleukin-2 production and clonal expansion. In contrast, CD8+ responses were transient. Proliferation and clonal expansion peaked on days 3 and 4, coincident with maximal expression of lytic effector function, and the cells then died. These results demonstrate that B7-1 mediated co-stimulation is sufficient for the induction of effector function in both helper and cytotoxic T cell precursors, but suggest that B7-1 co-stimulation is not sufficient to sustain helper-independent CD8+ CTL responses. When the dose responses of CD4+ and CD8+ T cells to B7-1 were compared, CD8+ T cells were found to require higher densities of B7-1 to attain an equivalent level of activation, suggesting that the level of expression of B7-1 by APC may influence the development of helper or CTL responses. Finally, in contrast to results obtained by others with B7-1 transfectants, purified B7-1 did not provide co-stimulation when presented on a surface separate from the TCR stimulus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9079798     DOI: 10.1002/eji.1830270305

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses.

Authors:  A Elbe-Bürger; A M Mommaas; E E Prieschl; E Fiebiger; T Baumruker; G Stingl
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  Immunomodulation of the anti-islet CD8 T cell response by B7-2.

Authors:  Deepak Yadav; Nora Sarvetnick
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

3.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

4.  Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Authors:  Sonja Obermann; Susanne Petrykowska; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

Review 5.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

Review 6.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

7.  B7-1/B7-2 blockade overrides the activation of protective CD8 T cells stimulated in the absence of Foxp3+ regulatory T cells.

Authors:  James M Ertelt; Esra Z Buyukbasaran; Tony T Jiang; Jared H Rowe; Lijun Xin; Sing Sing Way
Journal:  J Leukoc Biol       Date:  2013-06-06       Impact factor: 4.962

Review 8.  T cell immunotherapy enhanced by designer biomaterials.

Authors:  Zachary S Dunn; John Mac; Pin Wang
Journal:  Biomaterials       Date:  2019-06-14       Impact factor: 12.479

9.  The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses.

Authors:  Jacqueline M Tarrant; Joanna Groom; Donald Metcalf; Ruili Li; Bette Borobokas; Mark D Wright; David Tarlinton; Lorraine Robb
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

10.  Janus Nanoparticles for T Cell Activation: Clustering Ligands to Enhance Stimulation.

Authors:  Kwahun Lee; Yan Yu
Journal:  J Mater Chem B       Date:  2017-02-21       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.